The assessment of antimalarial drug efficacy

Trends in Parasitology

Volumn 18, Issue 10, 2002, Pages 458-464

  White, Nicholas J ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE;

CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; FOLLOW UP; HUMAN; IMMUNITY; NONHUMAN; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PROTOZOAL INFECTION; REINFECTION; RELAPSE; REVIEW; TIME; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; HUMANS; MALARIA, VIVAX; PLASMODIUM OVALE; PLASMODIUM VIVAX; RECURRENCE; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PROTOZOA;

EID: 0036790841     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(02)02373-5     Document Type: Review

References (33)

1. World Health Organization (1996) Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. WHO/MAL/96.1077
2. World Health Organization (1955) Chemotherapy of malaria. eds Covell G, Coatney GR, Field JW, Singh J. Monograph 27, WHO, Geneva
3. White N.J. Assessment of the pharmacodynamic properties of the antimalarial drugs in-vivo. Antimicrob. Agents Chemother. 41:1997;1413-1422.
4. Chotivanich K., et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J. Infect. Dis. 182:2000;629-633.
5. ter Kuile F., et al. Plasmodium falciparum: in-vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp. Parasitol. 76:1993;86-95.
6. White N.J., et al. Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. Lancet. 2:1989;1313-1316.
7. White N.J., Krishna S. Treatment of malaria: some considerations and limitations of the current methods of assessment. Trans. R. Soc. Trop. Med. Hyg. 83:1989;767-777.
8. Day N.P.J., et al. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood. 88:1996;4694-4700.
9. Yorke W., Mcfie J.W.S. Observations on malaria made during treatment of general paralysis. Trans. R. Soc. Trop. Med. Hyg. 18:1924;33-39.
10. Mayxay M., et al. Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am. J. Trop. Med. Hyg. 65:2001;918-923.
11. World Health Organization (2002) Monitoring antimalarial drug resistance. Report of a WHO consultation, WHO/CDS/CSR/EPH/2002.17
12. Simpson J.A., et al. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology. 124:2002;247-263.
13. de Vries P.J., et al. Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. Antimicrob. Agents Chemother. 44:2000;1302-1308.
14. World Health Organization . Chemotherapy of malaria and resistance to antimalarials. Report of a WHO Scientific Group. WHO Tech. Rep. Ser. 529:1973;30-35.
15. White N.J. Antimalarial drug resistance and mortality in falciparum malaria. Trop. Med. Int. Health. 4:1999;469-470.
16. Trape J.F. The public health impact of chloroquine resistance in Africa. Am. J. Trop. Med. Hyg. 64:2001;12-17.
17. Smithuis F.M., et al. Comparison of two mefloquine regimens for the treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob. Agents Chemother. 37:1993;1977-1981.
18. Simpson J.A., et al. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44:2000;3414-3424.
19. Viriyakosol S., et al. Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull. WHO. 73:1995;85-95.
20. Brockman A., et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am. J. Trop. Med. Hyg. 60:1999;14-21.
21. Farnert A., et al. Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans. R. Soc. Trop. Med. Hyg. 95:2001;225-232.
22. Garnham P.C.C. Malaria Parasites and Other Haemosporidia. 1966;Blackwell.
23. Pukrittayakamee S., et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob. Agents Chemother. 44:2000;1680-1685.
24. Fryauff D.J., et al. Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. Am. J. Trop. Med. Hyg. 59:1998;513-518.
25. Baird J.K., et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans. R. Soc. Trop. Med. Hyg. 90:1996;409-411.
26. Baird J.K., et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am. J. Trop. Med. Hyg. 56:1997;621-626.
27. Baird J.K. Primaquine as anti-relapse therapy for Plasmodium vivax. Trans. R. Soc. Trop. Med. Hyg. 92:1998;687.
28. Pukrittayakamee S., et al. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J. Infect. Dis. 169:1994;932-935.
29. White N.J. Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1999;739-749.
30. Maguire J.D., et al. Chloroquine resistant Plasmodium malariae in South Sumatra, Indonesia. Lancet. 360:2002;58-60.
31. Snow R.W., et al. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 17:2001;593-597.
32. Marsh K. Malaria disaster in Africa. Lancet. 352:1998;924.
33. White N.J., et al. Averting a malaria disaster. Lancet. 353:1999;1965-1967.